Oral Drug N-PPG Prevents Death in Mice with Rare Kidney Disease PH2

Oral Drug N-PPG Shows Promise in Preventing Fatal Kidney Disease in Mice

In a groundbreaking development, researchers at the Buck Institute have identified an oral drug, N-propargylglycine (N-PPG), that completely prevents death in mice suffering from a rare and deadly kidney condition known as Primary Hyperoxaluria Type 2 (PH2). The study, published in the prestigious Kidney International journal, highlights a potential breakthrough for treating this severe genetic disorder.

Understanding Primary Hyperoxaluria Type 2 (PH2)

PH2 is a genetic disorder characterized by the body's overproduction of oxalate, a substance that leads to the formation of calcium oxalate crystals. These crystals cause kidney stones, significant kidney damage, and often result in kidney failure, particularly affecting children and young adults. According to the Mayo Clinic, symptoms of PH2 include:

Sharp pain in the back, side, lower stomach, or groin
Pink, red, or brown urine due to blood
Frequent urge to urinate
Pain during urination
Inability to urinate or passing only small amounts
Chills, fever, upset stomach, or vomiting

Progression to kidney failure has been reported in up to 25% to 35% of patients in various large cohorts, often necessitating kidney or liver transplantation as a last resort.

—

Wide Pickt banner — collaborative shopping lists app for Telegram, phone mockup with grocery list

How N-PPG Works to Combat PH2

The drug N-PPG operates by targeting an enzyme called HYPDH/PRODH2 in the liver and kidneys, which is responsible for initiating oxalate overproduction from the breakdown of hydroxyproline, a component of collagen. Additionally, N-PPG induces a process known as "mitohormesis," a mild stress response that strengthens mitochondria, thereby enhancing kidney resilience.

To illustrate this mechanism, consider the body as a factory. Normally, proteins like collagen are broken down into smaller parts, producing glyoxylate, which is safely processed in healthy individuals. However, in PH2 patients, this process malfunctions, leading to glyoxylate buildup and excessive oxalate production, resulting in kidney stones and damage. N-PPG effectively halts this chain reaction by:

Completely preventing kidney stone formation
Protecting the kidneys from structural damage
Enabling normal survival in mice, despite the disease's typically fatal nature

As stated by the researchers, "Oral administration of N-PPG, a well-tolerated small-molecule inhibitor of Hypdh/Prodh2, significantly reduces hyperoxaluria and weight loss in Grhpr KO mice within three weeks, while preventing CaOx stone formation and kidney tubular damage."

Key Findings from the Study

In short-term trials, mice treated with N-PPG exhibited significantly lower oxalate levels in urine, fewer kidney stones, reduced kidney damage, and improved kidney function. A critical six-month survival test revealed that untreated PH2 mice succumbed to kidney failure by 15 weeks, whereas N-PPG-treated mice lived the full 24 weeks, matching healthy mice in survival rates, weight maintenance, and kidney health.

Significance and Broader Implications

This discovery is particularly important because current treatment options for PH2 are severely limited, often requiring invasive surgeries like kidney or liver transplants in severe cases. N-PPG offers hope for a real therapeutic solution rather than mere symptom management, potentially reducing the need for risky procedures and enhancing patients' quality of life. Although PH2 is rare, many cases remain undiagnosed, underscoring the need for effective treatments.

Moreover, researchers speculate that N-PPG could benefit a wider population. Its mechanism of action might help address more common kidney stone issues and other conditions by supporting cellular health and energy systems. The researchers noted, "Our findings establish N-PPG as a promising therapeutic candidate for the long-term prevention of CaOx kidney stone formation and kidney failure complications in PH2."